These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Rank MA; Oslie CL; Krogman JL; Park MA; Li JT Allergy Asthma Proc; 2008; 29(4):400-5. PubMed ID: 18702889 [TBL] [Abstract][Full Text] [Related]
46. Fear of repeated injections in children younger than 4 years receiving subcutaneous allergy immunotherapy. de Vos G; Shankar V; Nazari R; Kooragayalu S; Smith M; Wiznia A; Rosenstreich D Ann Allergy Asthma Immunol; 2012 Dec; 109(6):465-9. PubMed ID: 23176889 [TBL] [Abstract][Full Text] [Related]
47. Retrospective study of tolerance to short initiation schedules in subcutaneous immunotherapy. Gandarias B; Alonso MD; Fernández Rivas M; Fernández-Távora L; Miranda P; Muñoz Lejarazu D; Sotillo M; Tejero J; Rico P J Investig Allergol Clin Immunol; 2005; 15(4):242-8. PubMed ID: 16433204 [TBL] [Abstract][Full Text] [Related]
48. [Study on immunotherapy safety: clinical practice in allergy outpatient care]. Tomás-Pérez M; González-Cavero L; Domínguez-Ortega J Rev Alerg Mex; 2018; 65(4):357-361. PubMed ID: 30602205 [TBL] [Abstract][Full Text] [Related]
49. Comparison of systemic reactions in rush, cluster, and standard-build aeroallergen immunotherapy. Winslow AW; Turbyville JC; Sublett JW; Sublett JL; Pollard SJ Ann Allergy Asthma Immunol; 2016 Nov; 117(5):542-545. PubMed ID: 27788885 [TBL] [Abstract][Full Text] [Related]
50. The perception of allergen-specific immunotherapy among Italian general practitioners. Lombardi C; Bettoncelli G; Canonica GW; Passalacqua G Eur Ann Allergy Clin Immunol; 2012 Apr; 44(2):80-2. PubMed ID: 22768727 [TBL] [Abstract][Full Text] [Related]
51. Risk of anaphylaxis in cluster vs standard subcutaneous multiallergen immunotherapy. Chen JH; Orden T; Wang J; Sowho M; Tversky J Ann Allergy Asthma Immunol; 2023 May; 130(5):622-627. PubMed ID: 36521783 [TBL] [Abstract][Full Text] [Related]
53. Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life. Caminati M; Arcolaci A; Guerriero M; Manzotti G; Crivellaro M; Rolla G; Fassio F; Senna G Immunotherapy; 2019 Jun; 11(9):783-794. PubMed ID: 31094255 [No Abstract] [Full Text] [Related]
54. Effects of immunotherapy on Thai asthmatic children. Choovoravech P Asian Pac J Allergy Immunol; 1984 Jun; 2(1):32-6. PubMed ID: 6529481 [No Abstract] [Full Text] [Related]
55. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. Tinkelman DG; Cole WQ; Tunno J J Allergy Clin Immunol; 1995 Jan; 95(1 Pt 1):8-14. PubMed ID: 7822668 [TBL] [Abstract][Full Text] [Related]
56. [Use of specific immunotherapy in the Basic Health Area of Campiña Sur (Moguer-Huelva)]. Atienza Martín FJ; Márquez Ramírez P; Pérez Jigato R; Pérez Errazquin I; Alonso Pérez M; López Bueno N Aten Primaria; 2000; 26(3):169-71. PubMed ID: 10996950 [TBL] [Abstract][Full Text] [Related]
57. Seventh world congress on vaccines, immunisation and immunotherapy. Kurstak E Hum Vaccin; 2011; 7 Suppl():1. PubMed ID: 21546792 [No Abstract] [Full Text] [Related]
58. Letter from the editor. Ellis RW; Riedmann EM Hum Vaccin; 2011; 7 Suppl():2-3. PubMed ID: 21546793 [No Abstract] [Full Text] [Related]